Follow The Filings

BCRX Biocryst Pharmaceuticals Inc.

Health Care, filed as BIOCRYST PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 1 Owner
  • Max 0.8%
  • $4M
  • 1 reduce 1 exit

In 2026 Q2 Nathan Fischel trimmed Biocryst Pharmaceuticals, and Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.8% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.76%

Who owns BCRX

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.76%, was 0.93% Reduce −7.0% 400,248 $4M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 24,000 $228K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BCRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BCRX insider trades
  • None no insider bought on the open market
  • $605K sold by 2 insiders outside a trading plan
  • $3.5M sold by 2 insiders under 10b5-1 plans
  1. Amy E McKee Director
    Sale
    $100K 11,180 shares at $8.97 26% of stake
    Traded May 18 Filed May 19
    ↗
  2. Alane P Barnes Chief Legal Officer
    Planned sale
    $596K 62,500 shares at $9.54 14% of stake
    Traded May 13 Filed May 15
    ↗
  3. Theresa Heggie Director
    Sale
    $505K 49,933 shares at $10.11 43% of stake
    Traded Mar 20 Filed Mar 24
    ↗
  4. Alane P Barnes Chief Legal Officer
    Planned sale
    $1.4M 150,000 shares at $9.15 27% of stake
    Traded Mar 16 Filed Mar 18
    ↗
  5. Alane P Barnes Chief Legal Officer
    Planned sale
    $167K 21,773 shares at $7.65 5.2% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  6. Alane P Barnes Chief Legal Officer
    Planned sale
    $162K 21,210 shares at $7.65 6.3% of stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  7. Alane P Barnes Chief Legal Officer
    Planned sale
    $1.2M 161,680 shares at $7.21 32% of stake
    Traded Dec 1–3 Filed Dec 3, 2025
    ↗
  8. Machelle Sanders Director
    Planned sale
    $69K 9,600 shares at $7.14 24% of stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 8 option exercises, 6 share withholdings for taxes, 3 gifts, and 1 sale back to the company.

Congress

1 member of Congress traded BCRX in the last three years: 2 buys and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jul 10 filed Sep 4
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Nov 13, 2025 filed Dec 15, 2025

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K/A 2.05 Filing Doc
8-K 2.05,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $331.41M $450.71M $874.84M
Gross profit * $326.93M $438.44M $855.76M
Gross margin * 98.6% 97.3% 97.8%
Net income -$226.54M -$88.88M $263.86M
Net margin * -68.4% -19.7% 30.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $495.97M $421.97M $404.35M
Total non-current assets * $20.99M $68.45M $109.81M
Total assets $516.96M $490.42M $514.16M
Total current liabilities $149.99M $160.38M $196.07M
Total non-current liabilities * — $805.97M $437.24M
Total equity -$455.53M -$475.93M -$119.15M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$95.14M -$52.02M $347.37M
Cash from investing -$131.5M $52.59M -$13.69M
Cash from financing $32.48M -$5.76M -$349.93M
Net change in cash -$193.79M -$6.12M -$14.99M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.